RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals to Present at Investor Conferences in September

28 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

07 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

04 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

01 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

19 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

17 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

17 Jun 2023 14:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

22 May 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

08 May 2023 08:00:08 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 May 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

02 May 2023 07:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Apr 2023 16:01:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

27 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 Mar 2023 16:01:00 By Nasdaq GlobeNewswire